Erythropoietin in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Randomized, Double-Blind Trial

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Circulation. Cardiovascular Interventions

• Publication date

  2010-08-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIRCINTERVENTIONS.109.904425PMID 20736448
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.

  2008cited by this paper
• Evolution of left ventricular ejection fraction and its relationship to infarct size after acute myocardial infarction.

  2007cited by this paper
• Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure.

  2006cited by this paper
• A Single Bolus of a Long-acting Erythropoietin Analogue Darbepoetin Alfa in Patients with Acute Myocardial Infarction: A Randomized Feasibility and Safety Study

  2006cited by this paper
• Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo

  2005cited by this paper
• High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention.

  2005cited by this paper
• Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction.

  2005cited by this paper
• Mechanisms of erythropoietin‐mediated cardioprotection during ischemia‐reperfusion injury: role of protein kinase C and phosphatidylinositol 3‐kinase signaling

  2005cited by this paper
• Lack of acute cardioprotective effect from preischaemic erythropoietin administration in a porcine coronary occlusion model

  2005cited by this paper
• The role of anemia in the progression of congestive heart failure. Is there a place for erythropoietin and intravenous iron?

  2004cited by this paper
• Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia‐reperfusion injury

  2004cited by this paper
• Acute cardioprotective effects of erythropoietin in infant rabbits are mediated by activation of protein kinases and potassium channels

  2004cited by this paper
• Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization.

  2003cited by this paper
• Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling

  2003cited by this paper
• Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway.

  2003cited by this paper
• Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial

  2002cited by this paper
• Erythropoietin and VEGF exhibit equal angiogenic potential.

  2002cited by this paper
• Erythropoietin receptor mRNA expression in human endothelial cells.

  1994cited by this paper
• Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial.

  1987cited by this paper
• Factors that determine recovery of left ventricular function after thrombolysis in patients with acute myocardial infarction.

  1985cited by this paper

• Impact of Different Emergency Treatment Methods on Prognosis of Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Retrospective Study

  2024cites this paper
• Reperfusion injury in acute ischemic stroke: Tackling the irony of revascularization.

  2023cites this paper
• The temporal impact of erythropoietin administration on mitochondrial function and dynamics in cardiac ischemia/reperfusion injury.

  2022cites this paper
• Growth factor for therapeutic angiogenesis in ischemic heart disease: A meta-analysis of randomized controlled trials

  2022influential citation
• Pharmacologic Prevention of Myocardial Ischemia-Reperfusion Injury in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.

  2021cites this paper
• Erythropoietin Receptor/β Common Receptor: A Shining Light on Acute Kidney Injury Induced by Ischemia-Reperfusion

  2021cites this paper
• Potential Therapeutic Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in the Context of Ischemic Heart Failure: A State-Of-The-Art Review.

  2021cites this paper
• Anemia in Acute Coronary Syndrome: An Overview

  2021cites this paper
• Erythropoietin in Lupus: Unanticipated Immune Modulating Effects of a Kidney Hormone

  2021cites this paper
• SOCS3 deficiency in cardiomyocytes elevates sensitivity of ischemic preconditioning that synergistically ameliorates myocardial ischemia reperfusion injury

  2021cites this paper
• EPO And EPO-Receptor System As Potential Actionable Mechanism To Protection of Brain And Heart In Refractory Epilepsy And SUDEP.

  2020cites this paper
• Interleukin‐22 Directly Activates Myocardial STAT3 (Signal Transducer and Activator of Transcription‐3) Signaling Pathway and Prevents Myocardial Ischemia Reperfusion Injury

  2020cites this paper
• Erythropoietin Doping: Cardiovascular Effects in Athletes

  2020cites this paper
• Cardiac Regeneration and Repair: From Mechanisms to Therapeutic Strategies

  2020cites this paper
• Acute myocardial infarction and cardiogenic shock: Should we unload the ventricle before percutaneous coronary intervention?

  2020cites this paper
• Efficacy of IntraCoronary Erythropoietin Delivery BEfore Reperfusion-Gauging Infarct Size in Patients with Acute ST-segment Elevation Myocardial Infarction (ICEBERG).

  2019cites this paper
• Effects of Epoetin Alfa in STEMI patients Long term effects of Epoetin Alfa in patients with ST- elevation myocardial infarction

  2019cites this paper
• Erythropoietin Therapy in Critically Ill and Acute Kidney Injury Patients

  2019cites this paper
• Novel findings and therapeutic targets on cardioprotection of ischemia/reperfusion injury in STEMI.

  2019cites this paper
• Development of nanomedicines for inflammation disorders : evaluation of pharmacological efficacy on preclinical models

  2019cites this paper
• Low-Dose Erythropoietin in Patients With ST-Segment Elevation Myocardial Infarction (EPO-AMI-II)　- A Randomized Controlled Clinical Trial.

  2018cites this paper
• Erythropoietin reduces collagen deposition after myocardial infarction but does not improve cardiac function.

  2018cites this paper
• Peroxynitrite-matrix metalloproteinase and erythropoietin receptor signaling pathways in ischemic heart disease

  2017cites this paper
• Optimizing the host substrate environment for cardiac angiogenesis, arteriogenesis, and myogenesis

  2017cites this paper
• Hydrogel based approaches for cardiac tissue engineering.

  2017cites this paper
• Red Blood Cell Function and Dysfunction: Redox Regulation, Nitric Oxide Metabolism, Anemia

  2017cites this paper
• Erythropoietin and Its Derivatives: Mechanisms of Neuroprotection and Challenges in Clinical Translation

  2017cites this paper
• The Erythropoietin System Protects the Heart Upon Injury by Cardiac Progenitor Cell Activation.

  2017cites this paper
• Translational cardiac stem cell therapy: advancing from first-generation to next-generation cell types

  2017influential citation
• Impact of serum erythropoietin level on collateral vessel development in patients with coronary artery disease

  2017cites this paper
• Effect of Erythropoietin in patients with acute myocardial infarction: five-year results of the REVIVAL-3 trial

  2017cites this paper
• Harms of off-label erythropoiesis-stimulating agents for critically ill people.

  2017cites this paper
• Nanoplumbers: biomaterials to fight cardiovascular diseases

  2017cites this paper
• Early High-Dose Erythropoietin Therapy After Out-of-Hospital Cardiac Arrest: A Multicenter, Randomized Controlled Trial.

  2016cites this paper
• Baseline Hemoglobin Levels Associated with One-Year Mortality in ST-Segment Elevation Myocardial Infarction Patients.

  2016cites this paper
• Manifestations of Myocardial Ischemia / Reperfusion Injury in the Coronary Circulation

  2016cites this paper
• Ischemia reperfusion injury as a modifiable therapeutic target for cardioprotection or neuroprotection in patients undergoing cardiopulmonary resuscitation.

  2016cites this paper
• The Coronary Circulation as a Target of Cardioprotection.

  2016cites this paper
• The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge.

  2016cites this paper
• Novel, selective EPO receptor ligands lacking erythropoietic activity reduce infarct size in acute myocardial infarction in rats.

  2016cites this paper
• Promising strategies to minimize reperfusion injury in STEMI.

  2016cites this paper
• The use of pharmacological conditioning strategies to improve donor heart preservation in cardiac transplantation

  2016cites this paper
• Novel therapeutics in myocardial infarction: targeting microvascular dysfunction and reperfusion injury.

  2015cites this paper
• What is Wrong With Cardiac Conditioning? We May be Shooting at Moving Targets

  2015cites this paper
• Erythropoietin Reduces Post-PCI Arrhythmias in Patients With ST-elevation Myocardial Infarction

  2015cites this paper
• Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin.

  2015cites this paper
• Improving myocardial injury, infarct size, and myocardial salvage in the era of primary PCI for STEMI

  2015cites this paper
• Pharmacologic Therapy for Reducing Myocardial Infarct Size in Clinical Trials

  2015cites this paper
• Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning.

  2015cites this paper
• Administration of erythropoietin in patients with myocardial infarction: does it make sense? An updated and comprehensive meta-analysis and systematic review.

  2015cites this paper
• Ischaemic postconditioning: cardiac protection after the event

  2015cites this paper
• Investigational new drugs for the treatment of acute coronary syndrome

  2015cites this paper
• Combined treatment with erythropoietin and granulocyte colony‐stimulating factor enhances neovascularization and improves cardiac function after myocardial infarction

  2014cites this paper
• Adjuvant Cardioprotection in Cardiac Surgery: Update

  2014cites this paper
• Die Wirkung von Erythropoietin auf die Thrombozytenfunktion im akuten Myokardinfarkt

  2014influential citation
• Erythropoietin Responsive Cardiomyogenic Cells Contribute to Heart Repair Post Myocardial Infarction

  2014cites this paper
• Prognostic value of late gadolinium enhancement in cardiovascular magnetic resonance imaging after acute ST-elevation myocardial infarction in comparison with single-photon emission tomography using Tc99m-Sestamibi.

  2014cites this paper
• Safety and clinical outcome of erythropoiesis-stimulating agents in patients with ST-elevation myocardial infarction: a meta-analysis of individual patient data.

  2014cites this paper
• No post-conditioning in the human heart with thrombolysis in myocardial infarction flow 2-3 on admission.

  2014cites this paper
• The influence of Erythropoietin on platelet activation, thrombin generation and FVII/active FVII in patients with AMI

  2014cites this paper
• Pharmacologic Therapy That Simulates Conditioning for Cardiac Ischemic/Reperfusion Injury

  2014cites this paper
• Prognostic value of microvascular obstruction and infarct size, as measured by CMR in STEMI patients.

  2014cites this paper
• Erythropoietin Action in Stress Response, Tissue Maintenance and Metabolism

  2014cites this paper
• High‐dose erythropoietin for tissue protection

  2014cites this paper
• Erythropoietin and the heart: physiological effects and the therapeutic perspective.

  2014cites this paper
• Impact of Erythropoietin on Intensive Care Unit Patients

  2013cites this paper
• Safety of off-label erythropoiesis stimulating agents in critically ill patients: a meta-analysis

  2013cites this paper
• Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology.

  2013cites this paper
• Erythropoietin protects the systolic function of neonatal hearts against ischaemia/reperfusion injury.

  2013cites this paper
• Outcome after percutaneous coronary intervention

  2013cites this paper
• What is the Role of Erythropoietin in Acute Myocardial Infarct? Bridging the Gap Between Experimental Models and Clinical Trials

  2013cites this paper
• Myocardial infarction: cardioprotection by erythropoietin.

  2013cites this paper
• Myocardial ischemia-reperfusion injury: a neglected therapeutic target.

  2013cites this paper
• Cardioprotection: chances and challenges of its translation to the clinic.

  2013cites this paper
• Serum erythropoietin: a useful biomarker for coronary collateral development and potential target for therapeutic angiogenesis among the patients with coronary chronic total occlusion

  2013cites this paper
• Asialoerythropoietin Exerts Stronger Angiogenic Activity than Erythropoietin Via its Binding Affinity to Tissue

  2013cites this paper
• Long Term Effects of Epoetin Alfa in Patients with ST- Elevation Myocardial Infarction

  2013cites this paper
• Current State of Clinical Translation of Cardioprotective Agents for Acute Myocardial Infarction

  2013cites this paper
• High-Dose Erythropoietin in Acute ST-Segment Elevation Myocardial Infarction: A Meta-Analysis of Randomized Controlled Trials

  2013cites this paper
• Intracoronary administration of darbepoetin-alpha at onset of reperfusion in acute myocardial infarction: results of the randomized Intra-Co-EpoMI trial.

  2013cites this paper
• Erythropoietin in cardiac disease: effective or harmful?

  2013cites this paper
• Erythropoietin and the vascular wall: the controversy continues.

  2013cites this paper
• Effects of Erythropoietin on Blood Vessels and the Heart

  2013cites this paper
• Emerging Concepts in Myocardial Pharmacoregeneration

  2013cites this paper
• Conditioning the heart to prevent myocardial reperfusion injury during PPCI

  2012cites this paper
• Erythropoietin, progenitor cells and restenosis. A critique of Stein et al.

  2012cites this paper
• The use of erythropoiesis-stimulating agents in the intensive care unit.

  2012cites this paper
• Erythropoietin-induced progenitor cell mobilisation in patients with acute ST-segment-elevation myocardial infarction and restenosis

  2012influential citation
• Cardioprotection from ischemia/reperfusion injury: basic and translational research.

  2012cites this paper
• The effect of erythropoietin on normal and neoplastic cells

  2012cites this paper
• Current perspectives on protective roles of erythropoietin in cardiovascular system: erythropoietin receptor as a novel therapeutic target.

  2012cites this paper
• Erythropoietin attenuates the sequels of ischaemic spinal cord injury with enhanced recruitment of CD34+ cells in mice

  2012cites this paper
• Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial infarction: results of the erythropoietin in myocardial infarction trial.

  2012cites this paper
• Design and Rationale of Low-Dose Erythropoietin in Patients with ST-Segment Elevation Myocardial Infarction (EPO-AMI-II Study): A Randomized Controlled Clinical Trial

  2012cites this paper
• A novel synthetic derivative of human erythropoietin designed to bind to glycosaminoglycans

  2012cites this paper
• Percutaneous Coronary Intervention in Acute ST Segment Elevation Myocardial Infarction

  2012cites this paper
• Novel treatment strategies

  2012cites this paper
• Erythropoietin treatment in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials.

  2012cites this paper
• Did Clinical Trials in Which Erythropoietin Failed to Reduce Acute Myocardial Infarct Size Miss a Narrow Therapeutic Window?

  2012cites this paper
• Impact of an Interleukin-1 Receptor Antagonist and Erythropoietin on Experimental Myocardial Ischemia/Reperfusion Injury

  2012cites this paper